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Abstract
The clinical complexity of sepsis and the regional variability in renal
blood flow present a difficult challenge for the clinician or
investigator in understanding the role and clinical importance of
reduced blood flow in the pathophysiology of sepsis-induced acute
renal failure. Understanding the role of regional microvasculature
flow and interactions between endothelium and white blood cells
in the local delivery of oxygen and substrates is of critical
importance. Therefore, measuring total renal blood flow may not
permit an adequate understanding of the role of altered
hemodynamics in septic patients who develop acute renal failure.
Langenberg and colleagues [1] have completed an
exhaustive literature review documenting the effect of sepsis
on total renal blood flow (RBF) in humans and in animal
models of human sepsis. This is an extremely important area
of study because sepsis is the major cause of acute renal
failure (ARF) in hospitalized patients, the incidence of sepsis
is increasing at a rate of 1.5% per year [2], and the 28-day
mortality rate in cases of severe sepsis is as high as 50%
[2,3]. In a prospective study [4] the incidence of ARF in
sepsis was 19%, in severe sepsis it was 23% and in septic
shock it was 51%. Understanding the role, and the
determinants, of RBF alterations in the pathophysiology of
sepsis-induced ARF is therefore of critical clinical
importance.
The finding of heterogeneity in RBF during sepsis should be
of little surprise. First, sepsis is a heterogeneous disease
process for several reasons, including the bacteria (Gram-
negative or Gram-positive) or toxin (lipopolysaccharide; LPS)
involved, the route of delivery (intraperitoneal, intravenous, or
cecal ligation and puncture (CLP)), the rate of delivery, the
genetic make-up of the patient or animal (high versus low
cytokine responders), clinical stage of sepsis (early versus
late), and the associated co-morbid conditions (congestive
heart failure), to name just a few. For example, many previous
studies have used the administration of LPS in high dose to
initiate a ‘sepsis-like syndrome’ [5].
Although the LPS model can have a role in helping to
understand the sepsis phenotype, many investigators now
favor the use of the CLP model for several reasons. First,
sepsis is a complex phenomenon and although it is in part
due to the generation, release and biologic reactions of LPS,
additional factors are present in clinical sepsis that are more
completely modeled by bacterial-generated models such as
CLP [6]. Second, although both LPS and CLP models had
similar mortality rates, there were significant differences in the
kinetics and magnitude of cytokine production. The very rapid
production and extremely high levels of tumor necrosis factor-
α and cytokines in response to LPS resulted in a
vasoconstrictive phenotype with reduced cardiac output.
However, the CLP model resulted in an early hyperdynamic
phase characterized by low vascular resistance, low blood
pressure and increased cardiac output. These differences
were borne out in the review of the literature by Langenberg
and colleagues [1]. Perhaps the therapeutic approaches for
sepsis based on cytokine production after an LPS challenge
might therefore be misdirected because the LPS model does
not accurately reproduce the cytokine profile in sepsis.
The above-mentioned variables, plus additional variables
including the volume status of the animal, will then influence
the effect of sepsis on RBF in any clinical or experimental
setting. That cardiac output was the one determinant variable
of RBF, in a multi-variant analysis, is an important observation
on the essential role of cardiac output in patients with sepsis
and ARF. However, as pointed out by Langenberg and
colleagues [1], glomerular filtration rate can decrease even
with normal or increased cardiac output or RBF if there is a
disproportionate degree of vasodilatation between the
afferent and efferent arterioles. Probably even more important
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than this possibility is the effect of sepsis on the intra-renal
distribution of blood flow. The fact that total RBF is normal or
increased does not mean that reduced perfusion to
microvascular beds, and worsening hypoxia in these zones of
the kidney, is not leading to a cycle of continued inflammatory
response and the associated endothelial and epithelial cell
injury [7,8].
The heterogeneity and complexity of sepsis-induced
alterations in both total and regional RBF are therefore
clinically important but poorly understood. It will be crucial to
enhance our knowledge in this area as the search for
effective therapies to prevent and treat the devastating
disease of ARF associated with sepsis continues. New data
indicate that this understanding must extend to the level of
the regional microvasculature. Additionally, the role of
potential therapies to minimize inflammation, endothelial
dysfunction and the resulting interactions between
endothelium and white blood cells must be thoroughly
investigated.
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